IDiyas

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Michael Pourdehnad

USPTO Granted Patents = 17 

 

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 44(Granted Patents)


Company Filing History:

goldMedal17 out of 549 
 
Celgene Corporation
 patents

Years Active: 2016-2025

Loading Chart...
Loading Chart...
17 patents (USPTO):
1. 12396995 - Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use (2025-08-26),
2. 12178822 - Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion (2024-12-31),
3. 12103923 - Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (2024-10-01),
4. 12090147 - Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2024-09-17),
5. 11666579 - Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (2023-06-06),
6. 11628172 - Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (2023-04-18),
7. 11590117 - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2023-02-28),
8. 11583536 - Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use (2023-02-21),
9. 11390617 - Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione (2022-07-19),
10. 11241423 - Antiproliferative compounds and methods of use thereof (2022-02-08),
11. 10973822 - Combination therapy for treatment of hematological cancers and solid tumors (2021-04-13),
12. 10689708 - Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs (2020-06-23),
13. 10245258 - Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide (2019-04-02),
14. 10159675 - Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (2018-12-25),
15. 9968596 - Antiproliferative compounds and methods of use thereof (2018-05-15),

Title: The Innovative Contributions of Michael Pourdehnad in Hematology

Introduction: Michael Pourdehnad is a prominent inventor based in San Francisco, CA, whose work has significantly impacted the medical field, particularly in the treatment of hematological malignancies. With an impressive portfolio of 16 patents, Pourdehnad showcases a commitment to innovation in healthcare solutions.

Latest Patents: Among his latest contributions are two notable patents focused on methods for treating hematological malignancies and non-Hodgkin lymphoma. These patents describe the use of a specific compound, 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, for treating, preventing, or managing these serious conditions. The patents emphasize the compound's potential when used alone or in combination with rituximab, highlighting Michael's forward-thinking approach to oncology therapeutics.

Career Highlights: Michael Pourdehnad is associated with Celgene Corporation, a leading biopharmaceutical company. His role there has allowed him to engage in groundbreaking research aimed at discovering new treatment modalities for patients suffering from blood-related cancers. His dedication to advancing oncology treatments has positioned him as a key figure in the field.

Collaborations: Throughout his career, Pourdehnad has collaborated with notable colleagues, including Antonia Lopez-Girona and Kyle MacBeth. These partnerships reinforce the collaborative spirit in scientific research, fostering an environment where innovative ideas can flourish and translate into valuable therapies for patients.

Conclusion: Michael Pourdehnad remains an influential inventor in the realm of hematology. With his significant number of patents and commitment to developing new treatments, he plays a vital role in improving the lives of those affected by hematological malignancies. His contributions continue to pave the way for advancements in medical science and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…